Opthea’s Post

View organization page for Opthea, graphic

5,435 followers

In this month’s Retina Today edition, Fred Guerard, Opthea CEO, and a panel of retina experts discuss the potential of sozinibercept (OPT-302) to transform the wet AMD treatment landscape and address the unmet medical need for improved efficacy. Please click here to read the Retina Today insert online and learn more about the potential of sozinibercept (OPT-302) to redefine the treatment landscape for wet AMD.https://https://lnkd.in/eMM8bh47 #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics